| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
President, Regenerative Med. | EVP, Research and Development | Director +1 more
3 companies
Robert Benjamin Stein is President, Regenerative Med. at MDXG, with reported holdings spanning 3 companies. From April 2016 to May 2023, the filings on record show 0 open-market purchases and 12 sales. Robert Benjamin Stein's net worth is not public. Form 4 filings only show shares in the companies where this person is an insider; those holdings are worth an estimated $1.3M at current prices.
Our model assigns Robert Benjamin Stein a below-average insider score of 43/100, based on 14 past trades. Over a 12-month horizon, 14.3% of those trades were profitable, with an average 12-month return of -55.0%.
Robert Benjamin Stein's largest disclosed position is in MDXG as President, Regenerative Med., worth about $1.0M. The MDXG filings lean toward selling, a net 186,901 shares.
| Date | Ticker | Role | Type | Shares | Price | Value | Chg% | 3M | 12M | SEC |
|---|---|---|---|---|---|---|---|---|---|---|
| Mar 8, 2022 | MDXG Mimedx Group, Inc. | EVP, Research and Development | Sell | 11,672 | $4.86 | $56,714.25 | -6.4% | -19.7% | -15.5% | |
| Aug 16, 2021 | MDXG Mimedx Group, Inc. | EVP, Research and Development | Sell | 9,362 | $11.85 | $110,967.79 | -4.9% | -34.9% | -64.7% |